期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

非小细胞肺癌分子标志物研究进展

Advance on molecular markers of non-small-cell lung cancer
原文传递
导出
摘要 近年来，随着肿瘤分子生物学的不断发展，针对非小细胞肺癌（NSCLC）分子标志物的临床研究正如火如荼地开展，文章就NSCLC领域分子标志物的研究进展进行综述。 Clinical studies on non-small-cell lung cancer molecular markers have advanced lots of progress, which are benifited from the tumor molecular biology technology of development. The nearest studies and advances of non-small-cell lung cancer molecular markers are included in this paper.
作者 甄振华(综述) 詹必红(审校) 孙伟(审校)
机构地区 安徽省淮北市人民医院肿瘤科
出处 《肿瘤研究与临床》 CAS 2011年第8期570-574,共5页 Cancer Research and Clinic
关键词 癌 非小细胞肺 分子生物学 研究 Carcinoma, non-small-cell lung Molecular biology Research
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献43

  • 1Mork T,Wu YL,Thongprasert S,et al.Phase Ⅲ,randomised,open-label,first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer.European Society for Medical Oncology.Stockholm,Sweden:Annals of Oncology,2008.
  • 2Maemondo M,Inoue A,Kobayashi K,et al.Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.N Engl J Med,2010,362:2380-2388.
  • 3Zhou C,Yu YL,Chen G,et al.Efficacy results from the randomised phase OPTIMAL (CTONG 0802) study comparing first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM),in Chinese advanced non-small-cell lung cancer (NSCLC) patients (pts) with EGFR activating mutations.Ann Oncol,2010,21 (Supplement 8):Abstract LBA 13.
  • 4Shiota M,Fujimoto J,Semba T,et al.Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1lymphoma cell line,AMS3[J].Oncogene,1994,9:1567-1574.
  • 5Morris SW,Nacve C,Mathew P,et al.ALK,the chromosome 2 gene locus altered by the t (2;5) in non-Hodgkin's lymphoma,encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)[J].Oncology,1997,14:2175-2188.
  • 6Kwak EL,Camidge DR,Clark J,et al.Clinical activity ohserved in a phase I dose escalation trial of all oral c-met and ALK inhibitor,PF-02341066.J Clin Oncoi,2009,27:a3509.
  • 7Y.Bang,E.L.Kwak,A.T.Shaw,et al.Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC).J Clin Onco128:1 8s,2010 (suppl; abstr 3).
  • 8Sandier A,Gray R,Perry MC,et al.Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.N Engl J Med,2006,355:2542-2550.
  • 9Reck M,von Pawel J,Zatloukal P,et al.Phase Ⅲ trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer:AVAil.J Clin Oncol,2009,27:1227-1234.
  • 10Crin ò L,Dansin E,Garrido P,et al.Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL,MO19390):a phase 4 study.Lancet Oncol,2010,11:733-740.

二级参考文献10

  • 1Bepler G, Gautam A, Mclntyre LN, et al. Prognostic significance of molecular genetics aberrations on chromosome segment 11p15.5 in non-sman cell lung cancer.J Clin Oncol, 2002, 20(5): 1353-1360.
  • 2van Duin M, de Wit J, Odijk H, et al. Molecular characterization of the human excision repair gene ERCC-I: cDNA cloning and amino acid homology with the yeast DNA repair gene RADIO. Cell, 1986, 44(6): 913-923.
  • 3Tomkinson AE, BardweU AJ, Bardwell L, et al. Yeast DNA repair and recombination proteins Rad 1 and Rad i0 constitute a single-stranded-DNA endonuclease. Nature, 1993, 362(3426): 860-862.
  • 4Shirota Y, Stoehlmacher J, Brabender J, et al. ERCC 1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol, 2001, 19(23): 4298-4304.
  • 5Rouet P, Smih F, Jasin M. Introduction of double-strand breaks into the genome of mouse cells by expression of a rare-cutting endonuclease. Mol Cell Biol, 1994, 14(12): 8096-8106.
  • 6Liang E Han M, Romanienko PJ, et al. Homology-directed repair is a major double-strand break repair pathway in mammalian ceils. Proc Nail Acad Sci USA, 1998, 95(9): 5172-5177.
  • 7Slebos RJ, Hruban RH, Dalesio O, et al. Relationship between K-ras onco- gene activation and smoking in adenocarcinoma of the human lung. J Natl Cancer Inst, 1991, 83(14): 1024-1027.
  • 8Carbone DP, Mitsudoim T, Chiba I, et al. p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mtations in resected non small cell lung cancer: a preliminary report of LCSG 871. Chest, 1994, 106(6 suppl): 377S-381S.
  • 9Schiller JH, Adak S, Feins RH, et al. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy. J Clin Oncol, 2001, 19(2): 448-457.
  • 10Dabholkar M, Bostick-Bruton F. Weber C, et al. ERCC 1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer hast, 1992, 84(19): 1512-1517.

共引文献4

肿瘤研究与临床
2011年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部